Third Harmonic Bio
THRD
THRD was delisted on the 30th of July, 2025.
49 hedge funds and large institutions have $150M invested in Third Harmonic Bio in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 12 closing their positions.
2.31% more ownership
Funds ownership: 87.83% → 90.14% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $153M → $150M (-$3.41M)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 50 → 49 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.65M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.74M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$425K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$251K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.3M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$2.17M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.97M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.92M |
| 5 |
Millennium Management
New York
|
-$1.17M |
THRD Hedge Fund Activity: Q1 2023 in Review
49 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q1 2023, worth a combined $150M — down 2.2% from $153M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of THRD and 11 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 13 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $7.65M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.3M sold.
- 49 institutional investors held Third Harmonic Bio (THRD) as of Q1 2023, down from 50 in Q4 2022.
- Funds reported $150M of Third Harmonic Bio stock for Q1 2023, down 2.2% quarter-over-quarter.
- 11 funds opened new Third Harmonic Bio positions in Q1 2023 and 12 closed out, a net change of -1 holder.
- The largest Third Harmonic Bio buyer in Q1 2023 was EcoR1 Capital, an estimated $7.65M added.
- The largest Third Harmonic Bio seller in Q1 2023 was RA Capital Management, an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2023.